Abstract Number: 1177 • 2014 ACR/ARHP Annual Meeting
Evaluation of a Simplified Version of the Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) Comprising 5 Joints (RAMRIS5)
Background/Purpose Semi-quantitative measurement of inflammatory pathologies of the hand in magnetic resonance images (MRI) is a mandatory, but time-consuming task for MRI controlled studies in…Abstract Number: 1178 • 2014 ACR/ARHP Annual Meeting
Novel Quantification of MRI Provides a More Sensitive Outcome Measure Than Ramris
Background/Purpose There is increasing need for sensitive, objective outcome measures in rheumatoid arthritis (RA). MRI is more sensitive than clinical examination and X-rays, using a…Abstract Number: 1179 • 2014 ACR/ARHP Annual Meeting
Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: Sequential Evaluation Using Whole-Body Magnetic Resonance Imaging
Background/Purpose: Magnetic Resonance Imaging (MRI) has been established as a useful modality to evaluate synovitis, bone edema, and bone erosion in patients with rheumatoid arthritis…Abstract Number: 1180 • 2014 ACR/ARHP Annual Meeting
Dynamic Magnetic Resonance Imaging in the Assessment of the Response to Certolizumab Pegol in Rheumatoid Arthritis Patients: Results from a Phase IIIb Randomized Study
Background/Purpose Magnetic resonance imaging (MRI) can detect early joint inflammation with high sensitivity, without use of radiation. The MARVELOUS study (NCT01235598), using the OMERACT RA…Abstract Number: 1159 • 2014 ACR/ARHP Annual Meeting
Long-Term Quality of Life, Productivity Impairment, Disease Severity and Health Care Costs in Relation to Functional Impairment in Ankylosing Spondylitis Patients in the Czech Republic
Background/Purpose To describe the quality-of-life (QoL), productivity impairment, clinical indicators and health care costs in relationship to functional status described by Bath Ankylosing Spondylitis Functional…Abstract Number: 1158 • 2014 ACR/ARHP Annual Meeting
A Patient Survey Study of Zoledronic Acid Utilization and Factors Associated with Persistence
Background/Purpose: Persistence with osteoporosis therapies is associated with clinical outcomes. The goal of this study is to examine patient-reported persistence with zoledronic acid, a once-yearly…Abstract Number: 1157 • 2014 ACR/ARHP Annual Meeting
Delay in Diagnosis from Onset of Symptoms By More Than One Year in 31% of Patients with Different Rheumatic Diseases in Australia
Background/Purpose: Early treatment is regarded as critical for optimal clinical outcomes in patients with inflammatory rheumatic diseases. However, delayed diagnosis is recognized in many rheumatic…Abstract Number: 1156 • 2014 ACR/ARHP Annual Meeting
Satisfaction with Rural Rheumatology Telehealth Service
Background/Purpose: To assess patient satisfaction with the rheumatology telemedicine service provided to a rural town in northern Australia. Methods: A prospective, questionnaire-based exploratory study of…Abstract Number: 1155 • 2014 ACR/ARHP Annual Meeting
Economic Impact of Frequent Gout Flares in a Managed Care Setting
Background/Purpose Gout is the most common inflammatory arthritis in the US. For most patients, excruciatingly painful gout attacks (“flares”) are the major clinical burden of…Abstract Number: 1154 • 2014 ACR/ARHP Annual Meeting
Increasing Discrepancies Between Physician Assessment of Disease Activity and Patient Global Health in Germany Between 2000 and 2012
Background/Purpose We have seen remarkable achievements in disease control (DAS28) in rheumatoid arthritis in the past decade. They were, however, not accompanied to the same…Abstract Number: 1153 • 2014 ACR/ARHP Annual Meeting
Area of Residence and Socio-Economic Factors Significantly Affect Access to Biological Therapy for Rheumatoid Arthritis Patients in Romania
Background/Purpose Clinical trials have proven the efficacy of biological therapy for rheumatoid arthritis (RA) worldwide. However, high costs have set boundaries to their use, especially…Abstract Number: 1152 • 2014 ACR/ARHP Annual Meeting
Euroqol-5-Dimensions Utility Gain in Rheumatoid Arthritis, Treated with Abatacept, Rituximab, Tocilizumab or Tumor Necrosis Factor Inhibitors
Background/Purpose: We have earlier demonstrated that EuroQoL-5-Dimensions (EQ-5D) utility improves rapidly after commencement of tumor necrosis factor inhibition (TNFi) in rheumatoid arthritis (RA) and other…Abstract Number: 1151 • 2014 ACR/ARHP Annual Meeting
Barriers and Facilitators of a Career in Research Among Rheumatologists in the United States
Background/Purpose: Development of young rheumatology investigators is critical to the future of rheumatology. Beyond funding, the specific barriers to maintaining a career in rheumatology research…Abstract Number: 1150 • 2014 ACR/ARHP Annual Meeting
Marked Differences in Euro-Qol-5-Dimensions Preference Sets Based on Hypothetical or Experience Based Valuation
Background/Purpose: Health related quality of life (HRQoL) can be expressed as utility, a value anchored at 0 (death) and 1 (perfect health, forming the basis…Abstract Number: 1149 • 2014 ACR/ARHP Annual Meeting
Novel Adherence Measures for Infusible Therapeutic Agents in Rheumatoid Arthritis
Background/Purpose: Adherence is under consideration for quality reporting in a number of disease states. Published data on adherence of biologics reveal a wide range of…
ACR Meeting Abstracts